Kailera filed for a $528.5 million Nasdaq IPO, pricing 33.33 million shares at $14 to $16 each. Net proceeds come in at $458.7 million without the underwriter option, or $528.5 million if underwriters fully exercise their 30-day option on an additional 5 million shares.
The company raised $400 million in a 2024 Series A and $600 million in a 2025 Series B — the second-largest raise of that year. Ron Renaud, who led Cerevel Therapeutics before AbbVie bought it for $8.7 billion, runs the company.
What do public investors get? Four GLP-1 obesity drugs licensed from Jiangsu Hengrui Pharmaceuticals. The lead asset, injectable ribupatide, will absorb $625 million of combined IPO and existing cash to fund three global phase 3 trials through Q2 2028. Hengrui linked the drug to mean weight loss of nearly 18% at 48 weeks in a late-stage Chinese trial. Kailera hasn’t run a head-to-head trial against Eli Lilly’s Zepbound but has positioned it as a potential best-in-class offering.
Oral ribupatide gets $150 million for phase 3 trials beginning Q2 2028; it showed mean weight loss of up to 12.1% over 26 weeks in a Chinese trial. KAI-7535, a once-daily injectable small-molecule GLP-1, gets $50 million for phase 2 work while Hengrui advances it through phase 3 in China. A fourth asset, KAI-4729, is in phase 1 in China.
The IPO price range is set. The close date isn’t.
Diana Kowalski